Equities research analysts expect Natera, Inc. (NASDAQ:NTRA) to announce sales of $56.53 million for the current fiscal quarter, according to Zacks. Two analysts have made estimates for Natera’s earnings, with the highest sales estimate coming in at $57.66 million and the lowest estimate coming in at $55.40 million. Natera posted sales of $49.30 million in the same quarter last year, which suggests a positive year over year growth rate of 14.7%. The company is expected to announce its next earnings report on Tuesday, March 6th.

According to Zacks, analysts expect that Natera will report full year sales of $56.53 million for the current financial year, with estimates ranging from $212.50 million to $222.40 million. For the next year, analysts expect that the company will post sales of $264.42 million per share, with estimates ranging from $244.50 million to $287.10 million. Zacks’ sales calculations are an average based on a survey of analysts that that provide coverage for Natera.

Natera (NASDAQ:NTRA) last issued its earnings results on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.04). The company had revenue of $56.66 million during the quarter, compared to analyst estimates of $55.31 million. Natera had a negative net margin of 62.34% and a negative return on equity of 197.09%. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. During the same quarter last year, the company posted ($0.50) EPS.

A number of equities research analysts have recently issued reports on NTRA shares. Zacks Investment Research upgraded shares of Natera from a “sell” rating to a “buy” rating and set a $15.00 target price on the stock in a research note on Wednesday, October 11th. Robert W. Baird restated a “buy” rating on shares of Natera in a research note on Tuesday, October 24th. Canaccord Genuity restated a “buy” rating and issued a $15.00 target price on shares of Natera in a research note on Tuesday, November 14th. Morgan Stanley reaffirmed an “overweight” rating and set a $16.00 price objective (up previously from $13.00) on shares of Natera in a research report on Friday, October 6th. Finally, BidaskClub raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Natera presently has an average rating of “Hold” and an average price target of $15.00.

Several large investors have recently made changes to their positions in NTRA. Alliancebernstein L.P. grew its position in shares of Natera by 5.6% during the 1st quarter. Alliancebernstein L.P. now owns 26,600 shares of the medical research company’s stock valued at $236,000 after buying an additional 1,400 shares during the last quarter. TIAA CREF Investment Management LLC grew its position in shares of Natera by 14.3% during the 1st quarter. TIAA CREF Investment Management LLC now owns 93,901 shares of the medical research company’s stock valued at $833,000 after buying an additional 11,743 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Natera by 4.4% during the 1st quarter. Vanguard Group Inc. now owns 2,007,708 shares of the medical research company’s stock valued at $17,808,000 after buying an additional 84,144 shares during the last quarter. Geode Capital Management LLC grew its position in Natera by 4.8% in the 1st quarter. Geode Capital Management LLC now owns 235,287 shares of the medical research company’s stock worth $2,086,000 after purchasing an additional 10,813 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its position in Natera by 6.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 90,624 shares of the medical research company’s stock worth $804,000 after purchasing an additional 5,130 shares during the last quarter. 66.19% of the stock is owned by institutional investors and hedge funds.

Shares of Natera (NTRA) traded down $0.06 during trading on Thursday, hitting $9.53. 85,650 shares of the stock were exchanged, compared to its average volume of 192,520. The company has a current ratio of 1.85, a quick ratio of 1.75 and a debt-to-equity ratio of 2.43. Natera has a 1-year low of $7.35 and a 1-year high of $14.76.

WARNING: “$56.53 Million in Sales Expected for Natera, Inc. (NTRA) This Quarter” was posted by Watch List News and is the property of of Watch List News. If you are reading this report on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.watchlistnews.com/56-53-million-in-sales-expected-for-natera-inc-ntra-this-quarter/1764327.html.

About Natera

Get a free copy of the Zacks research report on Natera (NTRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with Analyst Ratings Network's FREE daily email newsletter.